advertisement

New insights into leukemic niche in bone marrow

50 %
50 %
advertisement
Information about New insights into leukemic niche in bone marrow
Health & Medicine

Published on January 17, 2009

Author: nanog

Source: slideshare.net

advertisement

New insights into leukemic microenvironment in bone marrow Alexey Bersenev’s journal club Jan. 16, 2009

What is the leukemic niche? Why does it matter? Leukemic microenvironment in bone marrow Hypothesis 1: Similar to normal HSCs - LSCs support hierarchy and depend upon interactions within a specific niche, the LSC niche. Hypothesis 2: If any interactions are specific only for LSC and their niches, they could be a target for therapy What do we know about it?

Human AML LSCs (CD34+/CD38-) in NOG model: 1. home to the endosteal niche of the bone marrow ; 2. win “engraftment competition” with normal hematopoietic stem cells ; 3. rest in G0 cell cycle phase ; 4. m ore likely this mechanism explains why LSCs are chemotherapeutically resistant and cause AML relapse

2. H uman mesenchymal stromal progenitor cells, derived from acute myelogenous leukemic bone marrow samples, have clonal genetic abnormalities (Michael Andreeeff, Blood (ASH Annual Meeting Abstracts) 2008 112: Abstract 2428 Right after winning the competition for the niche, cancer cells start to modify it, making it suitable for themselves. 1. Synergistic interactions between leukemic cells and osteoclast progenitors in bone microenvironment (Laura Calvi, Blood (ASH Annual Meeting Abstracts) 2008 112: Abstract 322) Abnormal cells in BM microenvironment and stroma:

Сell surface receptors expressed on HSC/progenitors, including CD44, ckit, CXCR4 and β1 integrins , seem to be vital for the localization and retention in the bone marrow Scheme of putative migration of stem cells between the bloodstream and bone marrow David A. Williams and Jose A. Cancelas (Nature 2006;444:828 )

1. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. (Krause DS, et al, Nat Med. 2006 Oct;12(10):1175-80) 2. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. (Jin L. et al, Nat Med. 2006 Oct;12(10):1167-74) Targeting of CD44

Targeting of CXCR4 1. The CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. (Azab AK, et al. Blood online Jan. 12, 2009) 2. Disruption of Leukemia/Stroma Cell Interactions by CXCR4 Antagonist CTCE-9908 Enhances Chemotherapy-Induced Apoptosis in AML (Michael Andreeff group, Blood (ASH Annual Meeting Abstracts) 2008 112: Abstract 2415

Questions: How do leukemic progenitors home and where do they stay in BM? How do normal HSC/progenitors interact with the leukemic microenviroment? How can we manipulate migration, homing and interaction of leukemic cells with their niches?

Models in vivo: Leukemia allogeneic: Donor – Nalm-6 pre-B ALL; Recipient: SCID Leukemia xenogeneic 1: human CD34+ transplant (before or after) in leukemic Nalm-6-GFP ALL Leukemia xenogeneic 2: Donor - human ALL/AML BM; Recipient: NOD/SCID Detection: Cell tracking techniques + real-time in vivo confocal and multiphoton microscopy imaging

Models in vivo:

Leukemia allogeneic: Donor – Nalm-6 pre-B ALL; Recipient: SCID

Leukemia xenogeneic 1: human CD34+ transplant (before or after) in leukemic Nalm-6-GFP ALL

Leukemia xenogeneic 2: Donor - human ALL/AML BM; Recipient: NOD/SCID

Few CD34+ cells co - localize with tumor upon homing to BM (day 0 ), yet CD34+ cells migrate into tumor niches over time

CD34+ cells in leukemic microenvironment do not response to G-CSF mobilization The malignant microenvironment, or niche, attracts CD34+ cells, but does not maintain CD34+ cell pool size or response to cytokine mobilization

CD34+ cell BM homing is inhibited by pertussis toxin (PTX) treatment in normal, but not leukemic mice Same results with AMD3100 CD34+ cells pre-treatment

AMD3100 does not restore CD34+ cell mobilization in leukemic mice.

SDF-1 ( red ) is highly expressed in the parasagittal sinusoidal region (CD34+ cell homing sites) of control mice Nalm-6–GFP cells ( green ) preferentially home to and proliferate in this area marked down-regulation of SDF-1 expression, here shown at 35 days after Nalm-6–GFP engraftment

CD34+ cells (white) home to the SDF-1–positive parasagittal vascular niches in control mice CD34+ cells aberrantly home to SDF-1+–negative, lateral regions in tumor ( green )–engrafted mice

In vivo imaging demonstrates increased SCF ( red ) expression in a tumor ( green ) - engrafted versus naïve mouse

SCF ( red ) expression is markedly up-regulated in ALL-engrafted versus control mice. CD34+ cells (white) localize to regions of high SCF expression

hSCF (brown) expression in tumor-engrafted BM Human BM biopsy Mouse model

Neutralizing treatment with anti-SCF inhibits CD34+ cell migration into tumor 7 days after CD34+ cell transplant into leukemic mice Same results in long-term (4 weeks)

Neutralizing anti-SCF restores G-CSF–mediated CD34+ cell mobilization in leukemic mice

Normal CD34+ cells engaged by the malignant niche exhibit abnormal behavior ( not maintain their cell pool size or response to cytokine mobilization ) SCF mediates CD34+ cell migration into the malignant niche, as well as mobilization failure and decrease in CD34+ cell number in leukemic mice. Targeting of SCF – cKit signaling could be potential therapeutic target for disruption leukemic niche Conclusions:

Normal CD34+ cells engaged by the malignant niche exhibit abnormal behavior ( not maintain their cell pool size or response to cytokine mobilization )

SCF mediates CD34+ cell migration into the malignant niche, as well as mobilization failure and decrease in CD34+ cell number in leukemic mice.

Targeting of SCF – cKit signaling could be potential therapeutic target for disruption leukemic niche

T herapeutic targeting of SCF may increase the hematopoietic reserve and improve outcomes in BM transplantation and autologous stem cell harvest in the setting of hematologic malignancy . Also it may improve HSC/progenitor mobilization in patients with leukemia (poor responders) Significance:

T herapeutic targeting of SCF may increase the hematopoietic reserve and improve outcomes in BM transplantation and autologous stem cell harvest in the setting of hematologic malignancy .

Also it may improve HSC/progenitor mobilization in patients with leukemia (poor responders)

"This is not a cure for leukemia , but it's one more tool. We like to hit cancer from all sides. This approach could potentially boost the immune system's response to the cancer by protecting the HPCs that are the source of mature immune cells. It could also maintain the patient's ability to tolerate treatment and to remain active." "If human stem cells respond in the same way as mouse cells do, it could buy us time to apply other therapies" D orothy S ipkins (U of Chicago) Citations:

Do leukemic cells create a new leukemic niche or do they modify already existent HSC niches? Do leukemic cells reorganize the molecular microenvironment specifically to entrap HPCs, or is the creation of competitive HPC niches a coincidental side effect of leukemic growth ? Is this behavior specific for leukemic cells or any cancer cells metastases in BM can create abnormal niches? What other possible mechanisms and pathways are involved? How we can manipulate interaction of leukemic cells with BM microenvironment more efficiently? Questions:

Do leukemic cells create a new leukemic niche or do they modify already existent HSC niches?

Do leukemic cells reorganize the molecular microenvironment specifically to entrap HPCs, or is the creation of competitive HPC niches a coincidental side effect of leukemic growth ?

Is this behavior specific for leukemic cells or any cancer cells metastases in BM can create abnormal niches?

What other possible mechanisms and pathways are involved? How we can manipulate interaction of leukemic cells with BM microenvironment more efficiently?

Not pure cell populations used in this study (CD34+ total), we don’t know about stem cells) Could NOG mice model be better to track of human leukemic cells? What happen with normal HSC after anti-SCF treatment? They should be there as well as some SCF backround in steady-state BM Possible disadvantages:

Not pure cell populations used in this study (CD34+ total), we don’t know about stem cells)

Could NOG mice model be better to track of human leukemic cells?

What happen with normal HSC after anti-SCF treatment? They should be there as well as some SCF backround in steady-state BM

Add a comment

Related presentations

Related pages

New insights into leukemic niche in bone marrow - HubSlide

New insights into leukemic niche in bone marrow. of 25. New insights into leukemic niche in bone marrow
Read more

Stem Cell Blog - New insights into leukemic ...

New insights into leukemic microenvironment in bone marrow. ... New insights into leukemic niche in bone marrow. ... a new insight about ‘leukemic niche ...
Read more

New insights into the normal and leukemic stem cell niche ...

New insights into the normal and leukemic stem cell niche: ... Van Etten, R. A. (2013), New insights into the normal ... niches within the bone marrow ...
Read more

Normal and Leukemic Stem Cell Niches: Insights and ...

Normal and Leukemic Stem Cell Niches: Insights and ... Leukemic cells create bone marrow niches that ... endosteal bone marrow niche into a self ...
Read more

New insights into leukemic microenvironment in bone marrow

In my opinion, the paper addresses a new insight about ‘leukemic niche’ and if the niche can be modulated therapeutically by neutralizing antibodies ...
Read more

The Bone Marrow Niche, Stem Cells, and Leukemia: Impact of ...

The Bone Marrow Niche, Stem Cells, and Leukemia: Impact of ... include bone marrow niche ... exposures into genomic investigations of ...
Read more

Maintenance of the hematopoietic stem cell pool in bone ...

Maintenance of the hematopoietic stem cell pool in bone marrow ... To provide new insights into the ... decreased in the bone marrow ...
Read more

Leukemia - Bone marrow vascular niche and the control of ...

Bone marrow vascular niche and the control of tumor growth in hematological malignancies. ... new insights into the ... bone marrow vascular niche: ...
Read more

Cytogenetics in benzene-associated myelodysplastic ...

Cytogenetics in benzene-associated myelodysplastic syndromes and acute myeloid leukemia: new insights into a ... cells in the bone marrow (BM) niche.
Read more